BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
12/10/2021 9:08:48 AM | Browse: 528 | Download: 1272
 |
Received |
|
2021-03-16 16:47 |
|
Peer-Review Started |
|
2021-03-16 16:54 |
 |
To Make the First Decision |
|
|
|
Return for Revision |
|
2021-05-01 04:55 |
|
Revised |
|
2021-05-12 15:20 |
|
Second Decision |
|
2021-11-25 05:35 |
|
Accepted by Journal Editor-in-Chief |
|
|
|
Accepted by Executive Editor-in-Chief |
|
2021-11-28 07:18 |
|
Articles in Press |
|
2021-11-28 07:18 |
|
Publication Fee Transferred |
|
|
|
Edit the Manuscript by Language Editor |
|
2021-11-24 03:35 |
|
Typeset the Manuscript |
|
2021-12-07 02:46 |
|
Publish the Manuscript Online |
|
2021-12-10 09:08 |
| ISSN |
1007-9327 (print) and 2219-2840 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Gastroenterology & Hepatology |
| Manuscript Type |
Minireviews |
| Article Title |
Transmembrane serine protease 2 and angiotensin-converting enzyme 2 anti-inflammatory receptors for COVID-19/inflammatory bowel diseases treatment
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Naser-Aldin Lashgari, Nazanin Momeni Roudsari, Saeideh Momtaz and Amir Hossein Abdolghaffari |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Amir Hossein Abdolghaffari, PhD, Assistant Professor, Department of Toxicology and Pharmacology, Faculty of Pharmacy, Tehran Medical Sciences, Islamic Azad University, No. 99, Yakhchal, Gholhak, Shariati St., Tehran 1941933111, Iran. amirhosein172@hotmail.com |
| Key Words |
Inflammatory bowel diseases; COVID-19; Transmembrane serine protease 2; Inflammation; Pro-inflammatory; Immunological responses |
| Core Tip |
This article provides clinical evidence on synthetic or natural-based transmembrane serine protease 2 (TMPRSS2) and angiotensin-converting enzyme 2 (ACE2) inhibitors, which are able to reduce coronavirus disease 2019-induced inflammation and cytokine storms in inflammatory bowel disease patients. Hence, targeting TMPRSS2 and ACE2 could be noticed as a novel approach for inflammatory bowel diseases treatment. |
| Publish Date |
2021-12-10 09:08 |
| Citation |
Lashgari NA, Roudsari NM, Momtaz S, Abdolghaffari AH. Transmembrane serine protease 2 and angiotensin-converting enzyme 2 anti-inflammatory receptors for COVID-19/inflammatory bowel diseases treatment. World J Gastroenterol 2021; 27(46): 7943-7955 |
| URL |
https://www.wjgnet.com/1007-9327/full/v27/i46/7943.htm |
| DOI |
https://dx.doi.org/10.3748/wjg.v27.i46.7943 |
© 2004-2025 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
